Lung Cancer: Lung Cancer II |

The Hedgehog Pathway Inhibitor GDC-0449 Alters the Expression Level of the Pathway Components In Lung Cancer Cell Lines FREE TO VIEW

Fei Tian, PhD; Rosemarie Kiefl; Amanda Tufman, MD; Rudolf Huber, MD
Author and Funding Information

University Hospital of LMU, Munich, Germany

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A299. doi:10.1016/j.chest.2016.02.312
Text Size: A A A
Published online


SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: The hedgehog signaling pathway (Hh) has been shown to be activated in cancer. GDC-0449 (Vismodegib) is a low-molecular Hh pathway inhibitor that binds to and inhibits Hh pathway receptor SMO. Recently, we could show that GDC-0449 is effective in lung cancer cell lines and that combination with cisplatin gives an additional effect. However, no data of the effect of GDC-0449 on Hh pathway component expressions in lung cancer cell lines is available.

METHODS: In order to detect the effect of GDC-0449 on the Hh pathway components, Shh, Patched, SMO, Gli-1 and Bmi-1 were examined by Western blot.

RESULTS: In both HCC and H1339 cell lines, the Hh pathway components showed substantial expression. In HCC cells, after the application of GDC-0449 50 µM, Gli-1, Patched and Shh expression decreased significantly compared with the control group by 43.9±11.2%, 55.9±10.0% and 65.2±7.8% respectively. In H1339 cells, after the treatment, Gli-1 expression reduced significantly by 46.8±8.9% and Shh and Bmi-1 expression increased by 100.7±6.2% and 120.1±8.0% compared with the control group (n = 3).

CONCLUSIONS: The stable expression of the Hh pathway proteins provides evidence of persistent activation of Hh signaling in lung cancer. GDC-0449 inhibits the Hh pathway function effectively by affecting the protein expression of the pathway partners, but in the two different cell lines, various mechanism presents and especially in SCLC H1339 cells, a compensation regulation might take place by the autocrine Shh and the up regulation of the expression of cancer stem cell related Bmi-1.

CLINICAL IMPLICATIONS: The further understanding of Hedgehog pathway's function in lung cancer will cast a light into the application of GDC-0449 and other Hh pathway inhibitors in lung cancer therapy.

DISCLOSURE: The following authors have nothing to disclose: Fei Tian, Rosemarie Kiefl, Amanda Tufman, Rudolf Huber

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543